Search Results - "Pérez Manghi, Federico C."

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes by Frías, Juan P, Davies, Melanie J, Rosenstock, Julio, Pérez Manghi, Federico C, Fernández Landó, Laura, Bergman, Brandon K, Liu, Bing, Cui, Xuewei, Brown, Katelyn

“…This open-label, 40-week, phase 3 trial assessed the efficacy and safety of tirzepatide, a weekly dual glucose-dependent insulinotropic polypeptide and…”
Get full text

84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2) by FRIAS, JUAN PABLO, DAVIES, MELANIE J., ROSENSTOCK, JULIO, PEREZ MANGHI, FEDERICO C., LANDO, LAURA FERNANDEZ, BERGMAN, BRANDON, LIU, BING, CUI, XUEWEI, BROWN, KATELYN

“…The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide (TZP) is in development for type 2…”
Get full text

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial by Del Prato, Stefano, Pavo, Imre, Weerakkody, Govinda J, Yang, Zhengyu, Aizenberg, Diego, Wynne, Alan G, Wiese, Russell J, Arora, Samir, Calderon, Rafael B, Butuk, David J, Chaychi, Leila, Curtis, Brian M, Chochinov, Ronald, Chow, Christopher, Cone, Clancy L, Dungan, Kathleen, Gaudiani, Linda, Herandez-Vazquez, Luis, Hsia, Stanley H, Kutner, Mark E, Loy, Juan, Miranda, Francisco G, Oliver, Michael J, Parke, Michael T, Philis-Tsimikas, Athena, Rosenstock, Julio, Sorial, Ehab, Stonesifer, Larry D, Stringam, Stanley, Van, Joanna T, Vazquez-Tanus, Jose B, Reyes, Ramon, Karimjee, Najmuddin, Martin, Earl E, Fraser, Neil J, Bhargava, Anuj, Wynne, Alan G, Billings, Liana, Walsh, Patrick, Shubrook, Jay, Knouse, Albert B, Mayfield, Ronald K, Bitar, Fahed G, de la Cuesta, Carmen, Morales Portillo, Cristobal J, Quesada Charneco, Miguel, Tofe Povedano, Santiago, Vazquez, Luis, Soto Gonzalez, Alfonso, Ciomos, Daniela, Neacsu, Valentina, Stern, Naftali, Sofer, Yael, Sack, Jessica, Tirosh, Amir, Shehadeh, Naim, Darawsha, Mahmud, Skripova, Dasa, Pavleova, Eva, Kubincova, Ludmila, Merciakova, Martina, St-Amour, Eric, Yared, Zeina, Blouin, Francois, Aggarwal, Naresh K, Bajaj, Harpreet, Tailor, Chetna, Egan, Alan, St.Onge, Natasha, Borges, Joao L C, Franco, Denise R, Souza, Filipe D, Russo, Luis Augusto T, Sassone, Sonia A, Steinacher, Andrea, Perez Manghi, Federico C, Orio, Silvia I, Gelersztein, Elizabeth, Fretes, José O, Calella, Pedro R F, Zaidman, Cesar J, Chertkoff, Alejandro, Gonzalez Galvez, Guillermo, Calvo, Cesar G, Sowinski, Dariusz, Jozefowska, Malgorzata, Skokowska, Ewa, Modzelewska, Anna, Gilfillan, Christopher, Morbey, Claire, Kaur, Kamal, Kemp, Laurence, Shea, Antony J, Kunitsyna, Marina A, Ou, Horng-Yih, Chen, Jung-Fu, Hwu, Chii-Min, Doupis, John, Pagkalos, Emmanouil, Mouslech, Zadalla

“…We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus…”
Get full text

Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100) by Sérusclat, Pierre, Belhatem, Narimène, Lingvay, Ildiko, Norwood, Paul C., Begtrup, Kamilla, Langbakke, Irene H., Pérez Manghi, Federico C.

Get full text

CA-190 - Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100) by Sérusclat, Pierre, Belhatem, Narimène, Lingvay, Ildiko, Norwood, Paul C., Begtrup, Kamilla, Langbakke, Irene H., Pérez Manghi, Federico C.

Get full text

23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR) by Buse, John B., Pérez Manghi, Federico C., García-Hernández, Pedro A., Norwood, Paul, Lehmann, Lucine, Tarp-Johansen, Mads Jeppe, Lingvay, Ildiko

Get full text

Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine by Lingvay, Ildiko, Norwood, Paul C., Begtrup, Kamilla, Langbakke, Irene H., Haynes, Marsha, Pèrez Manghi, Federico C.

Get full text

140 - Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine by Lingvay, Ildiko, Norwood, Paul C., Begtrup, Kamilla, Langbakke, Irene H., Haynes, Marsha, Pèrez Manghi, Federico C.

Get full text